Pfizer’s bet on bispecific antibodies gets a spookily timely endorsement from Nature Review Drug Discovery!
No sooner had my excitement over Pfizer’s tell-all oncology strategy on their 29th February 2024 innovation day abated from last week, then I get another follow-on burst of excitement this week! You may recall in my blog last week that Pfizer revealed they intended to get at least 8 oncology blockbusters by 2030. This is an absolutely huge ambition and huge target and so, how are they going to achieve this? By specifically zooming in on 3 modalities – 1) small molecules, 2) ADCs and 3) Bispecific Antibodies. You will already know how fond I am of ADCs, as this is an area that is already bursting with scientific and clinical activity.
What about bispecifics? Well, just a week on from the Pfizer innovation day, Nature Reviews Drug Discovery published a brilliant review on ‘The present and future of bispecific antibodies for cancer therapy’. Is this review spookily timely or what? Or is Nature Reviews Drug Discovery in cahoots with Pfizer? 😂. I’d like to say ‘Great minds think alike‘ and I’d definitely recommend reading this review and getting excited about what bispecifics might come out from the Pfizer engine-house in the near future.
READ THE ARTICLE – https://www.nature.com/articles/s41573-024-00896-6